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The different levels of knowledge described in a translational
pipeline (the connection of molecular mechanisms with pre-
clinical physiological and human health effects) are not
complete for many probiotics. At present, we are not in a
position to fully understand the mechanistic basis of many well
established probiotic health benefits which, in turn, limits our
ability to use mechanisms to predict which probiotics are
likely to be effective in any given population. Here we suggest
that this concept of a translation pipeline connecting
mechanistic insights to probiotic efficacy can support the
selection and production of improved probiotic products.
Such a conceptual pipeline would also provide a framework
for the design of clinical trials to convincingly demonstrate the
benefit of probiotics to human health in well-defined
subpopulations.
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Introduction
More than a century ago, Nobel-laureate Eli Metchnikoff
hypothesized that lactic acid bacteria can delay the dete-
rioration of health during aging due to their ability to
produce lactic acid and inhibit protein-fermenting intes-
tinal microbes. This was the beginning of the probiotic
concept, which is nowadays defined as ‘live microorgan-
isms that, when administered in adequate amounts, con-
fer a health benefit on the host’ [1,2]. A large variety of
products containing probiotics are consumed by millions
of people on a daily basis, and probiotics have an impres-
sive safety record. As of 2018, almost 2000 clinical studies
have reported on a variety of health benefits of probiotics,
including a recent landmark study that showed that a
probiotic/prebiotic mix resulted in a 40% reduction of
neonatal sepsis and death among infants in rural India
[3]. Meta-analyses support clinical benefits of the con-
sumption of probiotics in specific populations that are at
risk to develop a disease (Boxes 1 and 2 ). For many other
health benefits no generalized conclusions are possible
because, although individual studies have reported ben-
eficial effects in a variety of (intestinal) conditions [4],
these may be restricted to specific strains or specific
subpopulations [5]. In parallel, remarkable advances have
been made in understanding the wide array of molecular
mechanisms by which probiotic organisms can interact
with host cells [6], or how they can persist in [7] and/or
impact on the resident colonic microbiota [8,9]. However,
reliable translation of these mechanistic insights into
measurable clinical effects remains highly challenging.
Here we present a conceptual translational pipeline (Fig-
ure 1) that connects molecular mechanisms of bacterial
interactions with the host, to changes in host physiology,
and the corresponding health benefits in human applica-
tions. We employ this pipeline to evaluate how understand-
ing molecular interactions can assist the prediction of phys-
iological responses in preclinical models, with the ultimate
ambitionof translating these findings to beneficialoutcomes
in humans. Inversely, we use the pipeline concept to illus-
trate the importance of deciphering the physiological
changes in the host and the underlying molecular interac-
tion mechanisms involved in established probiotic health
benefits. Such knowledge could drive the development of
optimized probiotic products for those health benefits.
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Lactose maldigestion and yoghurt cultures
Although originally not intended as a health promoting
product, it is remarkable that the proven health benefit of
yogurt cultures in lactose maldigestion is supported by
understanding of the molecular mechanism involved.
Lactose maldigestion results from a genetic disposition
or acquired deficiency in the enzyme lactase, required for
hydrolysing lactose to glucose and galactose in the small
intestine of humans. If lactose reaches the colon it is
rapidly fermented by the microbiota, leading to gas
formation and symptoms that include bloating, diarrhoea,
flatulence, and vomiting. However, consumption of fer-
mented milk products, especially yogurt, containing high
levels of lactose is commonly tolerated in individuals
suffering from lactose maldigestion. This apparently con-
tradictory observation can be explained by the presence
of the lactase-like enzyme b-galactosidase in the yoghurt
bacteria Streptococcus thermophilus and Lactobacillus del-
brueckii subsp. bulgaricus. This bacterial enzyme can com-
pensate for the lack of lactase, thereby preventing the
fermentation of lactose in the large intestine and the
corresponding lactose maldigestion symptoms
[10,11,12,13]. This example links a discrete bacterial
activity (b-galactosidase) to a precise impact on physiol-
ogy (digestion of dietary lactose in the small intestine)
and a health benefit. Interestingly, the effect can in part
be recapitulated by ingestion of lactase tablets, further
validating this mechanistic interpretation. This
mechanistic knowledge allows the selection of yoghurt
cultures with enhanced b-galactosidase delivery capacity,
which could strengthen the lactose intolerance alleviating
capacity of yoghurt produced with such strains, thereby
illustrating the translational pipeline concept.
Exploring the translational pipeline concept
for the explanation and prediction of probiotic
effects
According to meta-analyses, the mitigation of antibiotic
associated diarrhoea (AAD; Box 1) and necrotizing
enterocolitis (NEC; Box 2) are among the best-documen-
ted clinical benefits of probiotics. The efficacy of a wide
range of probiotic strains suggests that they may have
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Box 1 Probiotics in AAD
Antibiotic associated diarrhoea (AAD) occurs in 5–39% of hospitalized
patients. A commonly reported AAD pathogen is Clostridium difficile,
but Candida albicans, Clostridium perfringens, Staphylococcus
aureus and Klebsiella oxytoca are also frequently observed [27]. Most
bacteria induce diarrhoea by the production of toxins [27,28], whereas
the yeast C. albicans can cause invasive candidiasis [29]. However,
these five pathogens together do not explain more than 30–40% of all
AAD cases, implying that other factors are involved.
Reducing the incidence or duration of AAD by consumption of
probiotics during the antibiotic treatment is one of the best-estab-
lished benefits of probiotics. Various probiotic products can reduce
relative AAD risk by more than 40%, while C. difficile associated
diarrhoea has been reported to be reduced by up to 60% with some
probiotics [15,16]. This finding suggests that many probiotics share
some ‘core properties’ which can ameliorate AAD [2]. The in vitro
investigation of pathogen inhibitory capacities of probiotic lactoba-
cilli and bifidobacteria in many cases depends on their capacity to
produce lactate and acetate and acidify their environment [30,31],
which is consistent with a generic mechanism of action in AAD.
However, more specific pathogen inhibition has been reported for
some probiotics and could involve the production of antimicrobial
peptides that inhibit enteric pathogens [32,33]. Antibiotic treatment
disrupts the intestinal microbiota and could compromise its
homeostatic interactions with the host mucosa. Probiotics were also
reported to influence AAD risk by improving the resilience of the
faecal microbiota [34], potentially through stimulation of specific
(lactate- and/or acetate-utilizing) members of the endogenous
microbiota [35]. Finally, most of the AAD associated pathogens
disturb the intestinal barrier, an effect that could be compensated by
probiotic stimulation of barrier integrity and/or repair [36,37].
Box 2 Probiotics in NEC
Necrotizing enterocolitis (NEC) is an inflammatory necrosis of the gut
of premature infants and symptoms include feeding intolerance,
bloated and sensitive abdomen, and bloody diarrhoea. NEC also
often leads to gastrointestinal perforations. It is a major cause of
mortality (estimated to be 20–50%) in neonatal intensive care units
throughout the world [38]. NEC is influenced by multiple factors,
including gestational prematurity, host genetics, enteral feeding,
mucosal injury, bacterial translocation, and inflammatory responses.
Although the involvement of intestinal bacteria with the onset of NEC
is not entirely clear, increased levels of pathobionts (e.g. Entero-
bacteriacae) often precedes the NEC diagnosis [39].
Multiple meta-analyses have evaluated the effect of probiotics in
NEC [40] and most have reached the conclusion that probiotic
treatment decreases the risk of NEC and mortality in premature
infants. A number of different probiotics appear to be effective,
suggesting a more generalized mechanism of action [2]. Neverthe-
less, Bifidobacterium probiotics appeared more effective than
Lactobacillus probiotics, and combination products (multiple spe-
cies and strains) appeared more effective than a single strain [17].
The higher efficacy of bifidobacteria probiotics could relate to their
capacity to utilize human milk oligosaccharides [41–43] and/or their
capacity to complement lactase limitation [12], which could con-
tribute to resolution of feeding intolerance. Despite these positive
effects, there is no clinical consensus for the prophylactic use of
probiotics as standard care in pre-term infants. Several concerns
have been raised concerning the non-uniformity of probiotic pro-
ducts tested, the consistent availability of effective products, and
their potential interaction with feeding regimes. These clinical con-
cerns are fuelled by the perceived safety risk of administering bac-
teria to a preterm infant with a known intestinal barrier defect.
Mechanistic studies on the role of probiotics in NEC largely depend on
animal models [44] or on in vitro cell culture systems. Probiotics have
been proposed to favourably affect intestinal colonization and thereby
reduce the risk of NEC, including the inhibition of Enterobacteriacae,
although the outcomes of studies in pigs have been inconsistent
[45,46]. Alternative mechanisms could include stimulation of mucosal
integrity and immune system function, which could reduce intestinal
permeability. For example, pilin expressing Lactobacillus rhamnosus
GG was shown to suppress TLR3, TLR4, and TIRAP-expression and
inflammatory responses in a foetal intestinal epithelial cell line, while not
affecting tolerance associated markers [47]. Bifidobacterium longum
subsp. infantis secretes a small glycan or glycolipid (5–10 kDa) that
prevents epithelial inflammatory responses by downregulating TLR4
and inflammatory signalling in various foetal cell culture models [48].
Despite these proposed mechanisms, there is no clarity on their roles in
probiotic benefits achieved in human NEC.
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shared core properties [2,14], which can positively influ-
ence host health in these conditions. However, the molec-
ular basis of these core properties remains not fully
understood [2,14] and there is no convincing mechanistic
explanation for probiotics in AAD or NEC (see Boxes
1 and 2). Several plausible mechanisms have been inves-
tigated which may contribute to the health benefits
observed, but in terms of our translational pipeline this
is an obvious gap hampering the development of
improved therapies. It could be argued that this is not
important since the positive effects of probiotic interven-
tions are reliably observed. However, some AAD and
NEC studies did not, or only marginally, reveal a positive
effect for probiotics [15–17]. A better understanding of
the relevant ‘core probiotic properties’ could help us to
design a more rational strategy to select and produce
reliably effective probiotics. This could be very valuable
if we are to overcome the understandable clinical
hesitation in deploying probiotics in the premature infant
population that suffers from NEC.
In other instances, precise mechanisms of probiotic inter-
action with host cells have been described and specific
probiotic effector molecules have been identified that can
elicit specific responses [6,18]. For some of these effector
molecules their capacity to elicit physiologically relevant
effects in preclinical (animal) models has been evidenced
successfully. However, as has been found with almost all
translational efforts across medicine, the predictive power
of how mechanistic knowledge may convert to reliable
clinical benefits in human populations remains limited.
For some health benefits, it is not realistic to expect that
clinical effects can be scientifically proven in human
populations. As an example, the role of bacteriocin pro-
duction in the ability of the probiotic Lactobacillus
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Schematic representation of the three layered translational pipeline that illustrates the connection of mechanistic knowledge of the probiotic-host
interactions and the molecules and structures involved, with the consequences of these interactions on host physiology and/or the demonstration
of health benefits in preclinical (animal) models (i.e. insight in the probiotic mode of action), and ultimately connecting to clinical studies that
demonstrate a health benefit in the target human (sub)population. The pipeline concept implies that knowledge of mechanisms of probiotic-host
interactions at molecular level can be employed to predict health benefits that these bacteria may elicit in selected human populations, while
inversely it can be employed to explain observed clinical effects in humans by linking to underlying modes of probiotic action. The connections
between the different layers of knowledge within the pipeline in the compelling example of the role of yoghurt bacteria in preventing lactose
maldigestion associated symptoms by in situ delivery of the bacterial b-galactosidase that supports small intestinal digestion of lactose is shown
on the right.
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salivarius UCC118 to reduce Listeria monocytogenes infec-
tion in vitro and in mice has been proven very elegantly
[19], but validation in humans could never be ethically
performed.
Is the translation of mechanistic
understanding truly failing?
We can question whether laboratory established molecu-
lar mechanisms do not translate to corresponding
responses in humans, or whether such responses do occur
but do not lead to a health benefit. As an example, it is
more than a decade ago that it was discovered that the
major secreted proteins (P40 and P75) of Lactobacillus
rhamnosus GG can protect mice against chemically
induced colitis. This effect depends on the capacity of
these proteins to modulate epidermal growth factor
receptor (EGF-R) activity, which leads to inhibition of
apoptosis and promotion of growth [20]. Recently, L.
rhamnosus GG was shown to promote epithelial wound
healing in skin and gingival human epithelial cell lines, a
process strongly controlled by EGF-R, and most likely
involving these major secreted proteins [21,22]. Remark-
ably, the duodenal tissue transcriptome responses in
healthy human volunteers upon L. rhamnosus GG con-
sumption revealed activation of ‘wound healing’ path-
ways, illustrating the legitimate molecular translation of
the EGF-R modulation by this probiotic from in vitro cell
lines to in vivo mucosal tissue [23]. This example high-
lights that challenges in translation may not be due to lack
of conservation of the molecular responses between in
vitro model systems and human mucosal tissues, but that
other factors like interindividual variability of the physi-
ological relevance of these responses may prevent the
demonstration of corresponding health benefits in human
subjects.
Concluding remarks
Translation of mechanistic understanding to reliable
clinical effects in human subjects is fraught with diffi-
culty. Human individuality and the highly distinct molec-
ular make-up of mucosal tissue was proposed as a key
confounder in the translation of molecular mechanisms
towards beneficial and perceivable physiological effects
in human subjects [23,24]. Moreover, randomized con-
trolled trials (RCTs) are considered by most regulatory
bodies as a sine qua non for demonstrating probiotic
efficacy. Many probiotic RCTs observe limited effect
sizes that may at least in part be due to the presence
of non-responders. Notably, the validity of RCT studies
depends on specific presuppositions intrinsic to the RCT
regimen, which may not be valid for probiotic interven-
tions [25]. Alternative clinical study designs (n-of-1 or
adaptation trial design [25]) may be needed to demon-
strate probiotic efficacy in specific subpopulations, and
with appropriate molecular read-outs can enable the
connection between mechanism of action and individu-
alized health effects.
Determining the mechanism of action of specific pro-
biotics is both scientifically satisfying and clinically
important. Filling in the gaps in our understanding of
the different layers of knowledge within the transla-
tional pipeline concept will help us to deliver appro-
priate and effective probiotic products to targeted
populations. Regulatory bodies also request such
understanding for approval of health claims. For exam-
ple, the European Food Safety Association (EFSA)
defines a mechanism of action as a biologically plausi-
ble sequence of events that lead to an observed effect,
which is supported by robust experimental observa-
tions and mechanistic information [26]. However, we
may not always require the unequivocal identification
of specific probiotic effector molecules, and in some
cases (e.g. AAD and NEC) it may be sufficient to
define core properties of probiotic products that can
be linked to the desired effect. These core properties
could relate to metabolites or structures that many
probiotics produce that may influence host responses
[2,14]. In other cases that involve species or strain-
specific effects, translation to reliable health benefits
can be driven by insights into the probiotic mode of
action and the effector molecules involved, but may
require stratification of subpopulations that would
benefit from a particular probiotic product. Therefore,
while it may not be necessary to complete the transla-
tional pipeline for well-established benefits, under-
standing mechanism of action of probiotics is critical
for the (i) selection of more effective probiotic strains;
(ii) optimization of probiotic product manufacturing
and quality assurance, (iii) improved design of probi-
otic formulation, and (iv) support the design of effec-
tive clinical trials with the best chance of realizing
benefits to human health. In general, the monitoring of
the production and bioavailability of known probiotic
core properties and/or specific effector molecules dur-
ing strain selection and product manufacturing and
formulation would result in improved probiotic-prod-
uct quality criteria relative to the number of viable
cells that is currently used.
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